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Purpose. Chronic low back pain (LBP) is often characterized by both nociceptive and neuropathic components. While various
monotherapies have been reported of only limited eﬃcacy, combining drugs with diﬀerent mechanisms of action and targets
appearsarationalapproach.Aimofthissystematicreviewistoassesstheeﬃcacyandsafetyofdiﬀerentcombinedpharmacological
treatments, compared to monotherapy or placebo, for the pharmacological treatment of chronic LBP. Methods. Published papers,
written or abstracted in English from 1990 through 2011, comparing combined pharmacological treatments of chronic LBP
to monotherapy or placebo were reviewed. Results. Six articles met the inclusion criteria. Pregabalin combined with celecoxib
or opioids was shown to be more eﬀective than either monotherapy. Oxycodone-paracetamol versus previous treatments and
tramadol-paracetamol versus placebo were also reported as eﬀective, while morphine-nortriptyline did not show any beneﬁt over
any single agent. Conclusions. In spite of theoretical advantages of combined pharmacological treatments of chronic LBP, clinical
studies are remarkably few. Available data show that combined therapy, including antinociceptive and antineuropathic agents is
more eﬀective than monotherapy, with similar side eﬀects.
1.Introduction
Successful treatment of chronic pain depends on identiﬁ-
cation of the involved mechanism and use of appropriate
therapeutic approaches. Woolf et al. [1] proposed that pain
symptoms and syndromes should be classiﬁed into two
broad mechanism-based pain categories: tissue-injury pain
(nociceptive) or nervous-system-injury pain (neuropathic).
Evenifthereisincreasingknowledgethatdiﬀerentmech-
anisms of pain require appropriate treatments and often
polypharmacotherapy, and although drug combination is
frequently empirically adopted in the clinical practice [2–5],
prospective studies concerning the relative eﬃcacyandsafety
of therapeutical drug associations to treat various painful
conditions are still remarkably few [6–10] and, as recently
reported, “more preclinical, clinical, and translational studies
are needed to improve the eﬃcacy of combination drug therapy
that is an integral part of a comprehensive approach to the
management of chronic pain”[ 11].
Although many patients have self-limited episodes of
acutelow-backpain(LBP)anddonotseekmedicalcare[12],
this condition is among the ﬁve most common reasons for
all physician visits in the USA [13, 14]. Among those who
do seek medical care, pain, disability, and return to work
typicallyimproverapidlyintheﬁrstmonth[15];however,up
to one-third of patients report persistent back pain of at least
moderate intensity one year after an acute episode [16, 17].
Medicationsarethemostfrequentlyrecommendedinter-
vention for low back pain [14, 18]. In one study, 80% of pri-
marycarepatientswithlowbackpainwereprescribedatleast
onemedicationattheirinitialoﬃcevisit,andmorethanone-
third were prescribed two or more drugs [5]. The most com-
monly prescribed medications for low back pain are nons-
teroidal anti-inﬂammatory drugs (NSAIDs), skeletal muscle
relaxants, and opioid analgesics [5, 19, 20]. Benzodiazepines,
systemic corticosteroids, antidepressant medications, and
antiepileptic drugs are also prescribed [21]. Monotherapies
of chronic LBP with NSAIDs, acetaminophen and tricyclic2 Pain Research and Treatment
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Figure 1: Flow diagram of inclusion and exclusion of articles for combined pharmacological interventions for chronic low back pain.
antidepressants, opioids, tramadol, benzodiazepines, andga-
bapentin (for radiculopathy) have all been found to provide
only a limited pain relief, ranging from 10 to 20 points on a
100-point visual analogue pain scale [22].
Chronic LBP has been shown to be the result of neu-
ropathic as well as nociceptive pain mechanisms and has
therefore been classiﬁed as a mixed pain syndrome [23–25].
Nonspeciﬁc nociceptive pain is the result of an inﬂammatory
response to tissue injury, while neuropathic pain describes
cutaneous projected pain arising from the lumbar spine
and/or nerve roots (radicular pain or radiculopathy) [3, 4].
The multifactorial nature of chronic LBP has often been
underrecognizedandundertreated.Thus,recentstudieshave
demonstrated that approximately 20–55% of patients with
chronic LBP have a >90% likelihood of a neuropathic pain
component and, in an additional 28% of patients, a neuro-
pathic pain component is suspected [5, 26, 27]. The presence
of a neuropathic pain component is associated with more
severe pain symptoms and higher healthcare utilization costs
[28].
Based on this evidence, it has been suggested that antide-
pressants and/or anticonvulsants in combination with either
opioids, traditional nonsteroidal anti-inﬂammatory drugs,
or muscle relaxants could be useful in the treatment of this
condition [27, 29, 30]. The aim of this systematic review is
to evaluate evidence for the eﬀectiveness of pharmacological
combination therapy in chronic LBP, with speciﬁc reference
to the management of nociceptive and neuropathic pain
components.
2.MaterialsandMethods
Published papers written in English or including an English
abstract, published from 1990 through 2011 and reporting
the results of a combined pharmacological treatment of
chronic lowback pain (LPB), compared with monotherapy
or placebo, were reviewed. To this aim, we searched inter-
national databases, including EMBASE, PubMed/Medline,
Google Scholar, SCOPUS, CINAHL, Cochrane Central Re-
gister of Controlled Trials, Cochrane Database of Sys-
tematic Reviews, http://www.google.com/,a n dhttp://www
.yahoo.com/. Inclusion criteria were the following:
(a) papers written or with an abstract in English;
(b) papers concerning the results of management of
chronic low-back pain (symptoms duration >6
months);
(c) treatment using a combination of two or more drugs,
versus monotherapy or placebo.
Two investigators, CR and ML, searched and reviewed
independently the literature and classiﬁed the references
found in terms of whether they should be included on basis
of the title and the abstract of the paper. In addition to
original study reports, review articles were also included and
the reference lists from all reviewed articles were assessed to
complete the literature search. At the end of the reviewing
process, the two reviewers’ lists of papers were compared and
if any discrepancy occurred, reclassiﬁcation was performed
according to the consensus reached.
This strategy identiﬁed 112 articles, the abstracts of
which were hand searched to identify a subset with the
speciﬁc focus of pharmacological treatment of chronic LBP
of relevance to the current review. Six studies on pharma-
cological management of chronic LBP (irrespective of the
cause) were identiﬁed as relevant and were included in this
paper (Figure 1).
3. Results
Table 1 summarizes the included studies examining com-
bination pharmacotherapy of chronic LBP. Three studies
evaluated paracetamol in combination with tramadol [35,
36]o ro x y c o d o n e[ 32].
In the ﬁrst study (n = 318), three-month treatment with
tramadol 37.5mg/paracetamol 325mg yielded signiﬁcantly
greater improvements in pain VAS score (P<0.015) and
Pain Relief Rating Scale score (P<0.001) than placebo.Pain Research and Treatment 3
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Signiﬁcant improvements were also observed for Roland
DisabilityQuestionnaire(RDQ)scores,severalofthesensory
Short-Form McGill Pain Questionnaire (SF-MPQ) items,
and the Role-Physical, Bodily Pain, Role-Emotional, Mental
Health, Reported Health Transition and Mental Component
items of the Short Form 36 (SF 36; all P<0.05). The
rates of discontinuation due to insuﬃcient pain relief were
signiﬁcantly lower with tramadol plus paracetamol (22.1%)
than for placebo (41.0%; P<0.001), and the proportion
of patients and investigators rating treatment as “good” or
“very good” was higher with combination therapy than with
placebo (P<0.001 for patients; P = 0.002 for investigators).
Adverse events were more common with the combination
(68.9%) than with placebo (46.5%), as were adverse drug
reactions (23.6% versus 3.8%) and rates of discontinuation
due to adverse events (18.6% versus 5.7%). Nausea, somno-
lence,andconstipationweresigniﬁcantlymorefrequentwith
combination treatment than with placebo (P<0.05) [36].
In the second study, patients with at least moderate
chronic LBP received tramadol 37.5mg/paracetamol 325mg
in a ﬁxed combination tablet; VAS scores after 3 months
were signiﬁcantly lower with tramadol/paracetamol than
with placebo (P<0.001). Combination therapy was also
associated with signiﬁcantly improved scores on several
measures, including RDQ score and physical-related items
on the SF-MPQ and SF-36 (P<0.05). Similar results to
those reported above by Ruoﬀ et al. [36] were observed for
discontinuationduetoinsuﬃcientpainrelief,theproportion
ofpatientsratingtreatmentas“good”or“verygood”andthe
incidence of adverse events [35].
Gatti et al., in a prospective observational study [32]
examined the eﬃcacy of a ﬁxed-dose combination of oxy-
codone plus paracetamol using the Pain Management Index.
Patientswerestratiﬁedaccordingtothepresenceofprevalent
osteoarticular pain (n = 78) or prevalent neuropathic pain
(n = 72). Combination therapy was associated with an im-
provement in pain in the majority of compliant patients,
although its beneﬁt in patients with neuropathic pain was
less marked.
Two papers reported on the eﬃcacy of pregabalin with,
respectively, celecoxib [31]o rt r a n s d e r m a l( T D S )b u p r e n o r -
phine [33]. In our previously published prospective, single-
blind, randomized study [31], the safety and eﬃcacy of the
association of celecoxib and pregabalin with either mono-
therapy for treatment of chronic low back pain of various
origin, were compared; data were also analyzed on the basis
of pain quality assessed with the Leeds Assessment of Neu-
ropathic Symptoms and Signs (LANSS) pain scale [37, 38].
Our study showed that the association pregabalin/celecoxib
resultedinastatisticallysigniﬁcantreductionofself-reported
pain when considering either all the recruited patients or
the subpopulations divided according to LANSS score. On
the contrary, celecoxib/placebo and pregabalin/placebo only
producedastatisticallysigniﬁcantreductionofreportedpain
in, respectively, patients with LANSS score <12 (P = 0.01)
(nociceptive pain) and in patients with LANSS score >12
(P = 0.03) (neuropathic pain), but not when including
all the patients. The drug combination also proved to be
more eﬀective than pregabalin alone or than celecoxib alone,
except for patients with LANSS score <12, in which treat-
ment combination or monotherapy provided similar results.
When all patients were considered, celecoxib alone provided
12.4% pain reduction, pregabalin alone 10.4%, and their
combination 38.2%. The largest pain reduction (51.8%)
was observed with the association pregabalin/celecoxib in
patients with LANSS score > 12. Pregabalin drug consump-
tion, when used in association with celecoxib, was signif-
icantly lower (P<0.05) compared to monotherapy. The
occurrence of side eﬀects was similar during either mono-
therapy or combination treatment [31].
Similarly, Pota and coworkers [33] found that the com-
bination of pregabalin and buprenorphine, TDS yielded
signiﬁcantly greater reductions in VAS scores than buprenor-
phine monotherapy (P<0.01). In the ﬁrst month of
therapy buprenorphine TDS alone provided a meaningful
pain reduction (VAS 82.75 ± 15 versus 38.25 ± 5, P<0.01);
at the end of the ﬁrst month, patients were then divided
in two groups: Group A receiving one-month therapy with
buprenorphine 35µg/mL plus pregabalin 150mg and Group
B buprenorphine plus placebo. At the end of the treatment,
only Group A presented a further reduction of the VAS
(P<0.01). The authors concluded that “buprenorphine TDS
determines a notable relief from pain. Moreover the association
of low doses of pregabalin allowed a further relief.”
The unique study evaluating the combination of mor-
phinewithnortriptyline[34],failedtoprovidesuﬃcientdata
as to regard the eﬃcacy of this free opioid-antidepressant
combination for the treatment of chronic LBP. In this study,
performed on 61 patients with sciatica, the combination of
morphine and nortriptyline did not reduce average leg pain
scores or any other leg or back pain scores, while 89% of pa-
tients receiving combination treatment reported an adverse
event, most commonly constipation.
4. Discussion
This systematic review shows that, in spite chronic LBP is
thought to be commonly the result of both nociceptive and
neuropathic mechanisms [23] and hence a rationale ap-
proach would be targeting the diﬀerent mechanisms of pain
by combining speciﬁc drug agents, remarkably few clinical
trials are currently available to validate this hypothesis.
This may due to diﬀerent reasons including
(i) the diﬃculty in designing/performing clinical trials
involving more treatments at the same time;
(ii) potential drugs’ interactions and possible adverse
eﬀects. Any speciﬁc combination of agents need to be
ﬁrst evaluated on the basis of the respective pharma-
cokinetic proﬁle and possible interactions and then
clinically tested. In free dose combinations, the onset
of adverse events can, to some extent, be overcome by
initiatingtreatmentatlowdosesandslowlyescalating
the dose until maximum analgesia or intolerable side
eﬀects arise; drug combination may also provide re-
duced consumption of any single drug and adverse
events comparable to monotherapy [31];6 Pain Research and Treatment
(iii) unpredictable dosing regimen. At variance with that
reported above concerning the possible advantage
of free dose combinations, ﬁxed dose are easier to
study and to market, being also likely associated with
greater patient’s compliance than free combinations;
however, identifying the best dose ratio for all the
patients, balancing the eﬃcacy and tolerability of any
single drug within a ﬁxed combination may be a
challenging exercise;
(iv) scarce economical interest of drug companies.
Allofthesepotentialdrawbacksmay,toadiﬀerentextent,
concurtoexplainthelimitedresearchondrugcombinations,
in spite of theoretical positive considerations and notwith-
standing the empirical widespread use of drug associations
in the clinical practice [5].
Among the six studies that were included in the present
review, two examined a ﬁxed-dose regimen of paracetamol
and tramadol combination against placebo [35, 36]. These
studies appear much similar, in their design and outcomes,
to a “traditional” monotherapy versus placebo study [39]
and do not really seem to add any insight as to concern the
control of diﬀerent types of pain.
On the contrary, the association of pregabalin plus cele-
coxib [31] or of pregabalin and an opioid agent [33]s e e m
more focused on targeting diﬀerent pain components of
chronic LBP.
Gabapentinoids have already been successfully used in
combination with other analgesic drugs to improve neuro-
pathic pain control. Gilron et al. [7] ﬁrst reported on the
eﬃcacy and safety of a combination of gabapentin and
morphine compared with that of each as a single agent in pa-
tients with painful diabetic neuropathy or postherpetic
neuralgia.In41patients,gabapentin-morphinecombination
showed signiﬁcantly better pain control (P<0.05) versus
placebo, gabapentin, and morphine. More recently, Gatti et
al. reported the Multicenter Italian Study, which compared
the eﬃcacy, safety, and quality of life of combination therapy
with controlled release (CR) oxycodone plus pregabalin
versus monotherapy in patients with neuropathic pain of
various origins [40]. This study showed in 409 patients that
the combination of CR oxycodone plus pregabalin was more
eﬀective than monotherapy for alleviating neuropathic pain
(P = 0.003) and to improve quality of life (P = 0.0009),
while combination therapy also allowed dose reduction of
both agents (22% for CR oxycodone and 51% for prega-
balin).
Interestingly, in our reported study, celecoxib or prega-
balin when used alone were shown to be not eﬀective in pa-
tients with, respectively, neuropathic or nociceptive low back
pain type, as evaluated with the LANSS pain scale [31]. This
is not surprising, given the speciﬁc ability of pregabalin to
control neuropathic pain [2, 41, 42], while celecoxib is a
selectiveCOX-2inhibitor thathasbeenprovedtobeeﬀective
in the treatment of diﬀerent pain models that are considered
predominantly of nociceptive origin [43, 44]. However, this
ﬁnding also supports the hypothesis of a better eﬃcacy of a
combined approach to the mixed pain conditions and points
out the importance of patient selection when evaluating the
analgesic eﬃcacy of any speciﬁc treatment.
Ar e c e n ts y s t e m a t i cr e v i e wo fp h a r m a c o l o g i c a l
monotherapies for chronic nonspeciﬁc low back pain
[45] showed no eﬀects of diﬀerent types of antidepressants,
compared to placebo, on any of the primary investigated
outcomes, including pain intensity, depression and func-
tional status. The study from Khoromi et al. [34], in a mixed
pain population, suﬀering from low back pain with lumbar
radiculopathy,seemstoconﬁrm,withthelimitationimposed
by the small sample size, that even nortriptyline alone or in
combination with morphine has limited eﬀectiveness.
Other frequently prescribed medications, like muscle
relaxants [19, 20] ,h a v en o tb e e ni n v e s t i g a t e di nr a n d o m i z e d
clinical trials for the treatment of chronic low-back pain [45]
and we could not ﬁnd any study regarding their use in a
combined pharmacological therapy of this condition.
It is worth noting how published comprehensive reviews
of clinical trials [46] and even the most recently reported
guidelines concerning the treatment of chronic low back
pain fail to address the use of combined pharmacological
treatments [47, 48]. While, in fact, several drugs are com-
pared and recommended as monotherapy, associations are
not mentioned. The paucity of the available data may well-
explain, in our opinion, the lack of indications in this regard
and points out the need for further research and well
designed clinical trials.
5. Conclusions
Pain treatment should be guided by the underlying mecha-
nisms and should take into consideration pain quality as well
aspainintensity.ChronicLBPoftencomprisesbothnocicep-
tive and neuropathic components, and various monother-
apies have been repeatedly reported as only partially ef-
fective. Therefore, an individualized, multimodal therapy,
combining drugs with diﬀerent mechanisms of action repre-
sents a rational approach. However, available studies investi-
gating drug combinations are remarkably few. In particular,
combination of pregabalin and celecoxib or buprenorphine
has been demonstrated to be more eﬀective that either
monotherapy and relatively safe. The association of parac-
etamol with tramadol or oxycodone has also been shown to
be eﬀective for reducing chronic low-back pain, even if not
evaluated against respective monotherapy. Further research
incombinedpharmacologicaltreatmentofchronicLBPwith
well-designed studies may oﬀer valuable tools for the clinical
practice and is strongly suggested.
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